Sotera Health, the medical-device sterilization and lab-testing company, received a vote of confidence from RBC this week. The Canadian bank argued that the company's free cash flow could jump in 2027 once a costly upgrade cycle winds down.
Sotera has been spending heavily to upgrade ethylene oxide facilities at its Sterigenics unit and to expand its "cobalt-loading" capacity—adding more radiation sources used in sterilization. RBC believes this spending is masking what the business can generate in cash today.
What's driving the spending?
Ethylene oxide is a gas widely used to sterilize medical devices, and Sotera's Sterigenics unit is one of the largest players in that space. The company has been investing to modernize these facilities, partly in response to tighter regulatory scrutiny and community concerns around ethylene oxide emissions. Separately, it's been expanding its cobalt-loading operations, which involve placing radioactive cobalt-60 sources into devices that then sterilize medical products through gamma radiation.
These are capital-intensive projects, and they've been eating into the cash Sotera generates from its operations. RBC expects capital expenditures to drop after the ethylene oxide work wraps up in the first quarter of 2027 and the cobalt-related investments finish. That, the bank says, could let free cash flow "materially grow" in 2027 without requiring faster revenue growth.
Why free cash flow matters
Free cash flow is the cash left after a company pays its operating costs and makes capital investments. It's the money a business can use to pay down debt, return to shareholders, or fund acquisitions. For investors, it's often a clearer measure of financial health than earnings, because it reflects actual cash generation rather than accounting adjustments.
RBC's case is that once Sotera's big projects are done, more of each dollar of profit should show up as cash. That would shift the story from "did earnings beat?" to "is the cash inflection on track?"
European concerns may be overblown
Investors have also been watching for softer European medical-technology procedure volumes, which could hurt demand for sterilization services. But RBC says that exposure is a relatively small share of Sotera's revenue and pointed to recent Sterigenics growth as a sign that US demand is holding up.
Sotera's latest quarter backed up the steadier view: adjusted earnings were $0.29 per share, ahead of FactSet's $0.27 estimate. That beat, while modest, suggests the company's core business is performing in line with or better than expectations.
What it means for investors
When a company is in a heavy spending phase, the market often cares less about small earnings surprises and more about whether the spending really rolls off on schedule. RBC's $24 price target leans on capex easing after Q1 2027. If the cash step-down arrives as planned, it can also widen Sotera's options: a stronger cash cushion can support debt reduction or bolt-on deals without stretching the balance sheet.
For everyday investors, the key signposts to watch are updates on project timelines, capex guidance, and cash conversion—not quarter-to-quarter volatility. If Sotera delivers on its spending plan, the company could emerge from this investment phase with a much healthier cash profile.
That kind of story—where heavy investment eventually turns into cash generation—is one that markets often reward, but only if the company executes on schedule. As with any capital-intensive business, delays or cost overruns could push the inflection point further out.
For a broader look at how healthcare stocks are moving, see our recent coverage of healthcare stocks splitting as some names jump and others fall. And for another example of how capital spending shapes a company's cash story, check out KEPCO's asset sale plans to fund grid upgrades.
